|
|
Vaccine Detail
|
Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: keyhole limpet hemocyanin (KLH) and proteins from the patient's tumor cells (NCT00923351)
- Immunization Route: Intradermal injection (i.d.)
- Description: Immune therapy using an experimental vaccine made from proteins from the patient's tumor cells may boost the body's immune response against the tumor. The effects of chemotherapy on the immune system can potentially make immunotherapy more effective if administered soon after completion of chemotherapy. The addition of recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7)) may make the immunotherapy more effective. Alpha cluster of differentiation 25 (CD25) and 8H9 depleted autologous lymphocytes plus tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccines plus or minus r-hIL7 (CYT107) may induce immune responses to tumor lysate in patients (with Ewing's sarcoma, rhabdomyosarcoma or neuroblastoma). (NCT00923351)
|
| Host Response |
|
|
| References |
NCT00923351: Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma [https://clinicaltrials.gov/study/NCT00923351]
|
|
